COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03274661
Recruitment Status : Recruiting
First Posted : September 7, 2017
Last Update Posted : September 20, 2019
Merck Sharp & Dohme Corp.
Miami Cancer Institute
Information provided by (Responsible Party):
Baptist Health South Florida

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 15, 2025
Estimated Study Completion Date : October 15, 2026